Mesothelioma Cancer Centers
Founded in 1904, Fox Chase Cancer Center was one of the first cancer hospitals in the United States. The cutting-edge spirit at Fox Chase did not stop there. The cancer center was one of the first centers to receive National Cancer Institute (NCI) designation and was a founding member of the National Comprehensive Cancer Network. The Center has also been the home of multiple Nobel laureates, recognized for their groundbreaking research.
Fox Chase Cancer Center offers a full spectrum of care for mesothelioma, led by experts in thoracic oncology. Their multidisciplinary team works together to give patients high-quality care from diagnosis to survivorship.
The center has an array of diagnostic testing available to patients, including PET and CT scans, fluid and tissue sampling and other imaging tests. Following diagnosis, pulmonary tests are conducted to assess lung function and determine the best possible method of treatment. Thoracic surgeons at Fox Chase are specialized in minimally invasive surgery and robotic surgery, as well as extrapleural pneumonectomy and pleurectomy treatments. Medical oncologists on staff will also help decide whether targeted therapies, chemotherapy or immunotherapy are right for the patient, depending on their response to surgical procedures.
Clinical trials are also offered at the discretion of a medical oncologist, who will develop a personalized treatment plan that best suits patient needs. Pulmonologists can also provide drainage treatments to treat pleural effusions, a common side effect of mesothelioma. Social work, palliative care, stress management and even wig fittings are available at Fox Chase for patients during and after their cancer treatment.
- Interventional Pulmonology
- Extrapleural pneumonectomy and pleurectomy
- Systemic therapy
- Radiation therapy
- Video-assisted thoracoscopic surgery (VATS)
- National Cancer Institute (NCI) Comprehensive Cancer Center
Mesothelioma Clinical Trials at Fox Chase Cancer Center
The following clinical trials are in progress or actively recruiting participants at Fox Chase Cancer Center:
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
Conditions: Advanced Malignancies; Metastatic Cancer Last Updated: May 3, 2019 Status: Recruiting
A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies
Conditions: Advanced Malignancies Last Updated: April 26, 2019 Status: Active, not recruiting
Pemetrexed Disodium/Observation in Treating Patients W/ Malignant Pleural Mesothelioma w/Out Progressive Disease After 1st Line Chemotherapy
Conditions: Malignant Mesothelioma Last Updated: March 4, 2019 Status: Active, not recruiting
Phase II MEDI4736 in Combination With Chemotherapy for First-Line Treatment of Unresectable Mesothelioma
Conditions: Mesothelioma; Pleural Mesothelioma Last Updated: July 5, 2018 Status: Active, not recruiting
Author: Linda Molinari
Editor in Chief, Mesothelioma Cancer AllianceRead about Linda
Reviewer: Annette Charlevois
Patient Support CoordinatorRead about Annette
Fox Chase Cancer Center. Mesothelioma.